These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34545416)

  • 21. Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis.
    Naicker SD; Feerick CL; Lynch K; Swan D; McEllistrim C; Henderson R; Leonard NA; Treacy O; Natoni A; Rigalou A; Cabral J; Chiu C; Sasser K; Ritter T; O'Dwyer M; Ryan AE
    Oncoimmunology; 2021 Jan; 10(1):1859263. PubMed ID: 33552684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
    van de Donk NWCJ; Usmani SZ
    Front Immunol; 2018; 9():2134. PubMed ID: 30294326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.
    Ogiya D; Liu J; Ohguchi H; Kurata K; Samur MK; Tai YT; Adamia S; Ando K; Hideshima T; Anderson KC
    Blood; 2020 Nov; 136(20):2334-2345. PubMed ID: 32844992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.
    Baumann N; Arndt C; Petersen J; Lustig M; Rösner T; Klausz K; Kellner C; Bultmann M; Bastian L; Vogiatzi F; Leusen JHW; Burger R; Schewe DM; Peipp M; Valerius T
    Front Immunol; 2022; 13():949140. PubMed ID: 36052078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [CD38 antibodies in multiple myeloma].
    Moreaux J
    Med Sci (Paris); 2019 Dec; 35(12):1001-1004. PubMed ID: 31903907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
    Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2553. PubMed ID: 30524421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
    Plesner T; van de Donk N; Richardson PG
    Cells; 2020 Feb; 9(2):. PubMed ID: 32041300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
    Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
    Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma.
    Zhang G; Guo C; Wang Y; Zhang X; Liu S; Qu W; Chen C; Yan L; Yang Z; Zhang Z; Jiang X; Chen X; Liu H; Lai Q; Wei X; Lu Y; Zhao S; Deng H; Wang Y; Yu L; Yu H; Wu Y; Su Z; Chen P; Ren Z; Yu M; Qu F; Luo Y; Gou L; Li Q; Huang Y; Ma F; Yang J
    J Hematol Oncol; 2022 Dec; 15(1):177. PubMed ID: 36581954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma.
    Stocker N; Gaugler B; Ricard L; de Vassoigne F; Marjanovic Z; Mohty M; Malard F
    Cancer Med; 2020 Mar; 9(6):2077-2084. PubMed ID: 31991058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma.
    Liu J; Xing L; Li J; Wen K; Liu N; Liu Y; Wu G; Wang S; Ogiya D; Song TY; Kurata K; Penailillo J; Morelli E; Wang T; Hong X; Gulla A; Tai YT; Munshi N; Richardson P; Carrasco R; Hideshima T; Anderson KC
    Nat Commun; 2024 Feb; 15(1):1367. PubMed ID: 38355622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity.
    Yu T; Qiao C; Lv M; Tang L
    BMC Biotechnol; 2019 May; 19(1):28. PubMed ID: 31118070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.
    Matas-Céspedes A; Vidal-Crespo A; Rodriguez V; Villamor N; Delgado J; Giné E; Roca-Ho H; Menéndez P; Campo E; López-Guillermo A; Colomer D; Roué G; Wiestner A; Parren PW; Doshi P; van Bueren JL; Pérez-Galán P
    Clin Cancer Res; 2017 Mar; 23(6):1493-1505. PubMed ID: 27637890
    [No Abstract]   [Full Text] [Related]  

  • 34. Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma.
    Vockova P; Svaton M; Karolova J; Pokorna E; Vokurka M; Klener P
    Folia Biol (Praha); 2020; 66(1):17-23. PubMed ID: 32512655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.
    Nijhof IS; Groen RW; Lokhorst HM; van Kessel B; Bloem AC; van Velzen J; de Jong-Korlaar R; Yuan H; Noort WA; Klein SK; Martens AC; Doshi P; Sasser K; Mutis T; van de Donk NW
    Leukemia; 2015 Oct; 29(10):2039-49. PubMed ID: 25975191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.
    Zhu C; Song Z; Wang A; Srinivasan S; Yang G; Greco R; Theilhaber J; Shehu E; Wu L; Yang ZY; Passe-Coutrin W; Fournier A; Tai YT; Anderson KC; Wiederschain D; Bahjat K; Adrián FJ; Chiron M
    Front Immunol; 2020; 11():1771. PubMed ID: 32922390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
    Xia C; Ribeiro M; Scott S; Lonial S
    Drugs Today (Barc); 2016 Oct; 52(10):551-560. PubMed ID: 27910963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolving Role of Daratumumab: From Backbencher to Frontline Agent.
    Jain A; Ramasamy K
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):572-587. PubMed ID: 32331971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma.
    Mustafa N; Nee AHF; Chooi JY; Toh SHM; Chung TH; Selvarajan V; Fan S; Ng SB; Poon M; Chan E; Lee J; Chee YL; Jeyasekharan AD; Zhou L; Yang J; Chng WJ
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells.
    Wang H; Koob T; Fromm JR; Gopal A; Carter D; Lieber A
    Cancer Biol Ther; 2024 Dec; 25(1):2314322. PubMed ID: 38361357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.